Schevaughn Carr Celestine
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 497 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Viiv Healthcare Company at 30.9% of the total. Among family clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 497 payments — averaging $40.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$6K
- Gilead$5K
- Novo Nordisk$3K
- Janssen Products, LP$1K
- AbbVie$1K
- Merck$1K
- plus $2K from 16 others
What the payments were for
- Food & beverage$20,02099%
- Education$1311%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 149 | $6,226 |
| Gilead | 113 | $5,254 |
| Novo Nordisk | 67 | $2,765 |
| Janssen Products, LP | 12 | $1,336 |
| AbbVie | 18 | $1,097 |
| Merck | 34 | $1,053 |
| Johnson & Johnson | 38 | $921 |
| GSK | 23 | $553 |
| Lilly USA, LLC | 10 | $218 |
| EMD Serono, Inc. | 9 | $201 |
| AstraZeneca | 7 | $138 |
| Theratechnologies Inc. | 3 | $78 |
| Bayer | 3 | $69 |
| Renalytix AI, Inc. | 2 | $45 |
| Sanofi-aventis U.S. LLC | 2 | $44 |
| Dexcom, Inc. | 1 | $32 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $27 |
| Shield Therapeutics Inc | 1 | $24 |
| Amgen | 1 | $21 |
| Organon | 1 | $17 |
| Althera Pharmaceuticals LLC | 1 | $16 |
| Pfizer | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,151 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 35 | $129,151 |
| OzempicSemaglutide | 112 | $103,217 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 11 | $40,989 |
| GlumetzaMetformin Hcl | 15 | $36,968 |
| DelstrigoDoravirine/Lamivu/Tenofov Diso | 11 | $27,591 |
| MounjaroTirzepatide | 20 | $26,895 |
| RybelsusSemaglutide | 19 | $24,213 |
| FarxigaDapagliflozin Propanediol | 17 | $8,314 |
| LinzessLinaclotide | 11 | $7,491 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $4,021 |
| Atorvastatin Calcium | 217 | $1,664 |
| Diclofenac Sodium | 18 | $1,412 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 25 | $811 |
| Enalapril Maleate | 74 | $760 |
| Amlodipine Besylate | 173 | $700 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya | $5,254 | $170,14046 claims |
| Novo NordiskOzempic, Rybelsus | $2,765 | $127,430131 claims |
| MerckDelstrigo, Janumet | $1,053 | $31,61222 claims |
| Lilly USA, LLCMounjaro | $218 | $26,89520 claims |
| AstraZenecaFarxiga | $138 | $8,31417 claims |
| AbbVieLinzess | $1,097 | $7,49111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.
Other family in Bronx
- Vladimir ByhovskyBronx$70K
- May YuBronx$24K
- Daphenie FauvelBronx$21K
- Nighat SaeedBronx$19K
- Keisha BallentineBronx$18K
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
- Sheri HillNorth Syracuse$165K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.